Results 1 to 10 of about 23,074,058 (199)

Disproportionality analysis of off-label intravitreal bevacizumab in the FDA Adverse Event Reporting System database [PDF]

Therapeutic Advances in Drug Safety
Background: Bevacizumab, an anti-vascular endothelial growth factor agent initially approved for cancer treatment, is widely used off-label in retinal vascular diseases; however, this use may carry safety risks, particularly when evidence from controlled
Homero Contreras-Salinas, Janet Cristina Vázquez-Beltrán, Gisela García-Sánchez, Sebastian Quirarte-Justo, Sarahí del Carmen Gómez-Macías, Lourdes Yolotzin Rodríguez-Herrera   +5 more
doaj   +3 more sources

Comparison of indices of disproportionality in PR systems [PDF]

Computer Science Journal of Moldova, 2012
Comparative analysis of 12 indices of disproportionality by such characteristics as: metric, definition domain, representation uniformity, invariance and utilization field, is done.
Ion Bolun
doaj   +5 more sources

The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline [PDF]

Frontiers in Pharmacology
Disproportionality analyses are the most-commonly used study design used in the post-marketing phase to detect suspected adverse drug reactions in individual case safety reports.
Michele Fusaroli, Francesco Salvo, Francesco Salvo, Charles Khouri, Charles Khouri, Emanuel Raschi   +5 more
doaj   +4 more sources

Anti-NMDA receptor encephalitis and vaccination: A disproportionality analysis

Frontiers in Pharmacology, 2022
Anti–N-methyl-D-aspartate receptor (NMDAR) encephalitis is an auto-immune neurological disorder characterized by the presence in the cerebrospinal fluid (CSF) of antibodies against the GluN1 subunit of NMDA receptors in the brain.
Salomé Martin, Brahim Azzouz, Aurore Morel, Thierry Trenque   +3 more
doaj   +3 more sources

Suspected Adverse Drug Reactions Related to Breast Cancer Chemotherapy: Disproportionality Analysis of the Brazilian Spontaneous Reporting System

Frontiers in Pharmacology, 2019
Spontaneous reporting systems may generate a large volume of information in real world conditions with a relatively low cost. Disproportionality measures are useful to indicate and quantify unexpected safety issues associated with a given drug-event pair
Flávia Campos Barcelos, Guacira Corrêa de Matos, Mario Jorge Sobreira da Silva, Fabrício Alves Barbosa da Silva, Elisangela da Costa Lima   +4 more
doaj   +1 more source

Risk of bronchospasm and coronary arteriospasm with sugammadex use: a post marketing analysis

Therapeutic Advances in Drug Safety, 2019
Introduction: Sugammadex is used for the reversal of neuromuscular blockade caused by rocuronium bromide and vecuronium bromide. As part of the post licensing phase of drug development, adverse events related to the use of sugammadex are still being ...
Pushkar Aggarwal
doaj   +1 more source

Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase

Pharmaceuticals, 2023
Cannabidiol is the first cannabis-derived drug approved for the treatment of Lennox–Gastaut syndrome, Dravet syndrome, and Tuberous Sclerosis Complex. In the current study, we performed a descriptive analysis followed by a disproportionality analysis of ...
Fabrizio Calapai, Carmen Mannucci, Liana McQuain, Francesco Salvo   +3 more
doaj   +1 more source

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data

BMC Cancer, 2023
Background Rucaparib has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. However, the long-term safety of rucaparib in large sample population was unknown. The
Qilin Zhang, Yiling Ding, Yamin Shu, Jing Chen   +3 more
doaj   +1 more source

Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database

Frontiers in Medicine
BackgroundThe development of Bruton's tyrosine kinase (BTK) inhibitors has revolutionized the management of B-cell malignancies and holds potential in autoimmune diseases.
Jiachen Tu, Jiachen Tu, Zhe Wang, Jingjing Zhang, Haojie Xu, Haojie Xu, Yanming Li, Li Zhang, Jian Gong, Libo Zhao   +9 more
doaj   +1 more source

Quantifying the Regional Disproportionality of COVID-19 Spread: Modeling Study

JMIR Formative Research
BackgroundThe COVID-19 pandemic has caused serious health, economic, and social consequences worldwide. Understanding how infectious diseases spread can help mitigate these impacts.
Kenji Sasaki, Yoichi Ikeda, Takashi Nakano   +2 more
doaj   +1 more source